Effects of exenatide and metformin in combination on some adipocytokine levels: A comparison with metformin monotherapy

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 9, 2013, Pages 724-732

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Franzetti, Ivano G ^c   Querci, Fabrizio ^d   Carbone, Anna ^e   Ciccarelli, Leonardina ^f   D'Angelo, Angela ^a   Fogari, Elena ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Alzano Lombardo   (Italy)

^e Hospital Center of Diabetes   (Italy)

^f Residenza Sanitario Assistenziale per Anziani (RSA) Villa Mafalda   (Italy)

Author keywords

C peptide; Exenatide; Homeostasis model assessment; Insulin resistance; Omentin 1; Retinol binding protein 4; Visfatin

Indexed keywords

ADIPOCYTOKINE; C PEPTIDE; EXENDIN 4; GLUCAGON; HEMOGLOBIN A1C; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROINSULIN; RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CELL FUNCTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADIPOKINES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTENTION TO TREAT ANALYSIS; ITALY; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 84883299366     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2012-0300     Document Type: Article

References (35)

1. Berg, J.K., Shenouda, S.K., Heilmann, C.R., Gray, A.L., and Holcombe, J.H. 2011. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregu-latory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes. Metab. 13(11): 982-989. doi:10.1111/j.l463-1326.2011.01428.x.
2. Bogardus, C. 1996. Metabolic abnormalities in the development of non-insulin-dependent diabetes mellitus. In Diabetes mellitus. Edited by D. LeRoith, S.I. Taylor, and J.M. Olefski. Lippincot-Raven Publishers. Philadelphia, Pa.
3. Bunck, M.C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., et al. 2009. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care, 32(5): 762-768. doi:10. 2337/dc08-1797.
4. Cechin, S.R., Pérez-Álvarez, I., Fenjves, E., Molano, R.D., Pileggi, A., Berggren, P.O., et al. 2012. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 21(4): 633-48. doi:10.3727/096368911X576027.
5. De Souza Batista, CM., Yang, R.Z., Lee, M.J., Glynn, N.M., Yu, D.Z., Pray, J., et al. 2007. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56(6): 1655-1661. doi:10.2337/db06-1506.
6. DeFronzo, RA. Lilly Lecture 1987.1988. The triumvirate: B-cell, muscle, liver. A collision responsible for NIDDM. Diabetes, 37: 667-687. doi:10.2337/diab.37. 6.667.
7. DeFronzo, RA., Tobin, J.D., and Andres, R. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237: E214-E223.
8. DeFronzo, RA, Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., and Baron, A.D. 2005. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28(5): 1092-1100. doi:10.2337/diacare.28.5.1092.
9. Derosa, G., and Maffioli, P. 2012. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr. Clin. Pharmacol. 7: 214-228. doi:10.2174/157488412800958686.
10. Derosa, G., D'Angelo, A., Tinelli, C, Devangelio, E., Consoli, A., Micoli, R., et al. 2007a. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 33: 129-134. doi:10. 1016/j.diabet.2006.11.008.
11. Derosa, G., Fogari, E., Cicero, A.F., D'Angelo, A., Ciccarelli, L., Piccinni, M.N., et al. 2007b. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hyper-tens. Res. 30: 387-394. doi:10.1291/hypres.30.387.
12. Derosa, G., Maffioli, P., Salvadeo, S.A., Ferrari, I., Ragonesi, P.D., Querci, F., et al. 2010. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol. Ther. 12(3): 233-240. doi:10.1089/dia.2009.0141.
13. Derosa, G., Putignano, P., Bossi, A.C., Bonaventura, A., Querci, F., Franzetti, I.G., et al. 2011. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur. J. Pharmacol. 666(1-3): 251-256. doi:10.1016/j.ejphar.2011.05.051.
14. Derosa, G., Carbone, A., Franzetti, I., Querci, F., Fogari, E., Bianchi, L., et al. 2012a. Effects of a combination of sitagliptin plus metformin vs metformin mono-therapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract. 98(1): 51-60. doi:10.1016/j.diabres. 2012.05.022.
15. Derosa, G., Ragonesi, P.D., Fogari, E., Cicero, A.F., Bianchi, L., Bonaventura, A., et al. 2012b. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam. Clin. Pharmacol. 2012. doi:10.1111/fcp.l2001.
16. Esteghamati, A., Noshad, S., Rabizadeh, S., Ghavami, M., Zandieh, A., and Nakhjavani, M. 2013. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul. Pept. 182: 1-6. doi:10.1016/j.regpep. 2012.12.005.
17. Fasching, P., Ratheiser, K., Nowotny, P., Uurzemann, S., Parzer, S., and Waldhäusl, W. 1994. Insulin production following intravenous glucose, argi-nine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism, 43:385-389. doi:10.1016/0026-0495(94)90109-0.
18. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of Insulin. Science, 307:426-430. doi:10.1126/science.l097243.
19. Hug, C, and Lodish, H.F. 2005. Medicine. Visfatin: a new adipokine. Science, 307: 366-367. doi:10.1126/science.H06933.
20. Körner, A., Garten, A., Blüher, M., Tauscher, R., Kratzsch, J., and Kiess, W. 2007. Molecular characteristics of serum visfatin and differential detection by im-munoassays. J. Clin. Endocrinol. Metab. 92: 4783-4791. doi:10.1210/jc.2007-1304.
21. Kralisch, S., Klein, J., Bluher, M., Paschke, R., Stumvoll, M., and Fasshauer, M. 2005. Therapeutic perspectives of adipocytokines. Expert Opin. Pharmaco-ther. 6: 863-872. doi:10.1517/14656566.6.6.863.
22. Li, L, Yang, G., Li, Q., Tan, X., Liu, H., Tang, Y., et al. 2008. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes. Metab. 10: 921-930. doi:10.1111/j.l463-1326.2007.00832. X.
23. Lichtenstein, A.H., Appel, L.J., Brands, M., Carnethon, M., Daniels, S., Franch, HA., et al. 2006. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler. Thromb. Vase. Biol. 26: 2186-2191. doi:10.1161/01ATV.0000238352.25222.5e.
24. Mogensen, C.E., Keane, W.F., Bennett, P.H., Jerums, G., Parving, H.H., Steffes, M.W., et al. 1995. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet, 346(8982): 1080-1084. doi:10.1016/ S0140-6736(95)91747-0.
25. Preumont, V., Hermans, M.P., Brichard, S., and Buysschaert, M. 2010. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab. 36: 293-298. doi:10.1016/j.diabet.2010.02.001.
26. Rydén, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.J., et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart. J. 28: 88-136. doi:10. 1093/eurheartj/ehl260.
27. Schaffler, A., Neumeier, M., Herfarth, H., Fürst, A., Schölmerich, J., and Büchler, C. 2005. Genomic structure of human omentin, a new adipocyto-kine expressed in omental adipose tissue. Biochim. Biophys. Acta, 1732: 96-102. doi:10.1016/j.bbaexp.2005.11.005.
28. Takebayashi, K., Suetsugu, M., Wakabayashi, S., Aso, Y., and Inukai, T. 2007. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J. Clin. Endocrinol. Metab. 92: 2712-2719. doi:10.1210/jc.2006-1249.
29. Tobin, G.S., Cavaghan, M.K., Hoogwerf, B.J., and McGill, J.B. 2012. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int. J. Clin. Pract. 66: 1147-1157. doi:10.1111/ijcp.l2032.
30. Weir, G.C., and Leahy, J.L. 1994. Pathogenesis of non-insulin-dependent (type II) diabetes mellitus. Injoslin's diabetes mellitus. 13th ed. Edited by C.R. Kahn and G.E. Weir. Lea and Febiger. Philadelphia, Pa. pp. 240-264.
31. Winer, B.J. 1971. Statistical principles in experimental design. 2nd ed. McGraw-Hill, New York, N.Y.
32. World Health Organization. 2009 Global Database on Body Mass Index: BM Classification. Available from http://apps.who.int/bmi/index.jsp?introPage=intro_3.html [Accessed 2013 April 7].
33. Yang, Q., Graham, T.E., Mody, N., Preitner, F., Peroni, O.D., Zabolotny, J.M., et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436: 356-362. doi:10.1038/nature03711.
34. Yang, R.Z., Lee, M.J., Hu, H., Pray, J., Wu, H.B., Hansen, B.C., et al. 2006. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290: E1253-E1261. doi:10.1152/ajpendo.00572.2004.
35. Yilmaz, Y., Yonal, O., Kurt, R., Alahdab, Y., Eren, F., Ozdogan, O., et al. 2011. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand. J. Gastroenterol. 46: 91-97. doi:10.3109/00365521.2010.516452.